PMID- 34791236
OWN - NLM
STAT- MEDLINE
DCOM- 20220509
LR  - 20220530
IS  - 1460-2083 (Electronic)
IS  - 0964-6906 (Linking)
VI  - 31
IP  - 9
DP  - 2022 May 4
TI  - Heterogeneity analysis of the immune microenvironment in laryngeal carcinoma 
      revealed potential prognostic biomarkers.
PG  - 1487-1499
LID - 10.1093/hmg/ddab332 [doi]
AB  - Laryngeal squamous cell cancer (LSCC) is the second most prevalent malignancy 
      occurring in the head and neck with a high incidence and mortality rate. 
      Immunotherapy has recently become an emerging treatment for cancer. It is 
      therefore essential to explore the role of tumour immunity in laryngeal cancer. 
      Our study first delineated and evaluated the comprehensive immune infiltration 
      landscapes of the tumour microenvironment in LSCC. A hierarchical clustering 
      method was applied to classify the LSCC samples into two groups (high- and 
      low-infiltration groups). We found that individuals with low immune infiltration 
      characteristics had significantly better survival than those in the 
      high-infiltration group, possibly because of the elevated infiltration of immune 
      suppressive cells, such as regulatory T cells and myeloid-derived suppressor 
      cells, in the high-infiltration group. Differentially expressed genes between two 
      groups were involved in some immune-related terms, such as antigen processing and 
      presentation. A univariate Cox analysis and least absolute shrinkage and 
      selection operator analysis were performed to identify an immune gene-set-based 
      prognostic signature (IBPS) to assess the risk of LSCC. The prognostic model 
      comprising six IBPSs was successfully verified to be robust in different cohorts. 
      The expression of the six IBPSs was detected by immunohistochemistry in 110 cases 
      of LSCC. In addition, different inflammatory profiles and immune checkpoint 
      landscape of LSCC were found between two groups. Hence, our model could serve as 
      a candidate immunotherapeutic biomarker and potential therapeutic target for 
      laryngeal cancer.
CI  - (c) The Author(s) 2021. Published by Oxford University Press. All rights reserved. 
      For permissions, please e-mail: journals.permissions@oup.com.
FAU - Qian, Zhipeng
AU  - Qian Z
AD  - The First Affiliated Hospital, Hengyang Medical School, University of South 
      China, Hengyang, Hunan 421001, China.
AD  - College of Bioinformatics Science and Technology, Harbin Medical University, 
      Harbin China.
FAU - Shang, Desi
AU  - Shang D
AD  - The First Affiliated Hospital, Hengyang Medical School, University of South 
      China, Hengyang, Hunan 421001, China.
AD  - College of Bioinformatics Science and Technology, Harbin Medical University, 
      Harbin China.
FAU - Fan, Lin
AU  - Fan L
AD  - Department of Otolaryngology-Head and Neck Surgery, the Second Affiliated 
      Hospital of Harbin Medical University, Harbin China.
FAU - Zhang, Jiarui
AU  - Zhang J
AD  - Department of Otolaryngology-Head and Neck Surgery, the Second Affiliated 
      Hospital of Harbin Medical University, Harbin China.
FAU - Ji, Linhao
AU  - Ji L
AD  - Department of Otolaryngology-Head and Neck Surgery, the Second Affiliated 
      Hospital of Harbin Medical University, Harbin China.
FAU - Chen, Kexin
AU  - Chen K
AD  - Department of Pathology, the Third Affiliated Hospital of Harbin Medical 
      University, Harbin China.
FAU - Zhao, Rui
AU  - Zhao R
AUID- ORCID: 0000-0002-6602-6583
AD  - Department of Otolaryngology-Head and Neck Surgery, the Second Affiliated 
      Hospital of Harbin Medical University, Harbin China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (Biomarkers)
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Biomarkers
MH  - Biomarkers, Tumor/genetics
MH  - *Carcinoma, Squamous Cell/genetics
MH  - Humans
MH  - *Laryngeal Neoplasms/genetics
MH  - Prognosis
MH  - Tumor Microenvironment/genetics
EDAT- 2021/11/19 06:00
MHDA- 2022/05/10 06:00
CRDT- 2021/11/18 07:23
PHST- 2021/07/19 00:00 [received]
PHST- 2021/11/08 00:00 [revised]
PHST- 2021/11/08 00:00 [accepted]
PHST- 2021/11/19 06:00 [pubmed]
PHST- 2022/05/10 06:00 [medline]
PHST- 2021/11/18 07:23 [entrez]
AID - 6427352 [pii]
AID - 10.1093/hmg/ddab332 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2022 May 4;31(9):1487-1499. doi: 10.1093/hmg/ddab332.